We need your help! If you've ever found our data helpful, please take our impact survey (15 min). Your replies will help keep the data flowing to the scientific community. Please Click here for Survey


Dataset Information


New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.

ABSTRACT: Many different aberrations in the Anaplastic Lymphoma Kinase (ALK) were found to be oncogenic drivers in several cancers including neuroblastoma (NB), therefore ALK is now considered a critical player in NB oncogenesis and a promising therapeutic target. The ALK-inhibitor crizotinib has a limited activity against the various ALK mutations identified in NB patients. We tested: the activity of the novel ALK-inhibitor X-396 administered alone or in combination with Targeted Liposomes carrying ALK-siRNAs (TL[ALK-siRNA]) that are active irrespective of ALK gene mutational status; the pharmacokinetic profiles and the biodistribution of X-396; the efficacy of X-396 versus crizotinib treatment in NB xenografts; whether the combination of X-396 with the TL[ALK-siRNA] could promote long-term survival in NB mouse models. X-396 revealed good bioavailability, moderate half-life, high mean plasma and tumor concentrations. X-396 was more effective than crizotinib in inhibiting in vitro cell proliferation of NB cells and in reducing tumor volume in subcutaneous NB models in a dose-dependent manner. In orthotopic NB xenografts, X-396 significantly increased life span independently of the ALK mutation status. In combination studies, all effects were significantly improved in the mice treated with TL[ALK-siRNA] and X-396 compared to mice receiving the single agents. Our findings provide a rational basis to design innovative molecular-based treatment combinations for clinical application in ALK-driven NB tumors.


PROVIDER: S-EPMC4745691 | BioStudies | 2015-01-01


REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5715105 | BioStudies
1000-01-01 | S-EPMC3129808 | BioStudies
1000-01-01 | S-EPMC3242652 | BioStudies
2016-01-01 | S-EPMC4726162 | BioStudies
2016-01-01 | S-EPMC4885798 | BioStudies
2015-01-01 | S-EPMC5242382 | BioStudies
2014-01-01 | S-EPMC4215402 | BioStudies
2020-01-01 | S-EPMC7524717 | BioStudies
2016-01-01 | S-EPMC4755925 | BioStudies
2019-01-01 | S-EPMC6883072 | BioStudies